Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Investor Presentation (December 2018)
23 slides from Harrow's investor presentation, Dec 17, 2018
Slide 1: Imprimis Pharmaceuticals December 2018
imprimi PHARMACEUTICALS NASDAQ: IMMY DECEMBER 2018
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assump
Slide 3: To ensure patient access to affordable healthcare solutions
To ensure patient access to affordable healthcare solutions We own large equity interests ina growing and diversified portfolio of pharmaceutical businesses we’ve founded and royalties on certain drug candidates they are developing
Slide 4: Imprimis, Park
| 2014 | | 2015 2017 | [ 2018 ] | 2018 imprimis, PARK COMPOUNDING * 238% revenue CAGR in ophthalmology (2014-2017) + 153% consolidated revenue CAGR (2014-2017) * 60+ formulation and method of use patent filings Gurta ce MELT * Balance sheet value in retained equity positions * Significant cash flow
Slide 5: Imprimis operating and development companies
e e e e o%e ee e@eese IMpPrimMis PHARMACEUTICALS IMPriMIs p élon : elon mpc G@urtace MELT COMPOUNDING Mayfield Pharmaceuticals Radley Pharmaceuticals In Development for 2019 In Development for 2019
Slide 6: 100% Ownership Operating Businesses
100% OWNERSHIP OPERATING BUSINESSES 4 VW IMPFIMIS p- PARK COMPOUNDING
Slide 7: ImprimisRx: what is it and the opportunity
IMPFINUS p WY PARK COMPOUNDING WHAT IS IT? + ImprimisRx is the leading ophthalmology compounding business in the U.S. Serve ophthalmologists treating cataracts, LASIK, glaucoma, and dry eye 3,000+ physician customers (and growing) ordering “20 SKUs IP focused; 60+ patents filed 2Mt+ sterile doses di
Slide 8: Financial Performance
$9,000 FINANCIAL @ CONSOLIDATED | cyavonrsenreerstommes PERFORMANCE #7900 (IN THOUSANDS) $6,000 $5,000 $4,000 $3,000 $2,000 $1,000 Trends $0 04-2016 Q1-2017 Q2- 2017 Q3- 2017 Q4- 2017 Qt- 2018 2 - 2018 Q3 - 2018 Revenue Growth: 2014-2017 Revenue 65% 39% 40% 34% 27% 45% 51% 66% * 238% CAGR (ophthalmi
Slide 9: Ophthalmology Revenue Goal Roadmap
OPHTHALMOLOGY REVENUE GOAL ROADMAP IMPFIMIS p OPPORTUNITY IN U.S. | FY 2021: $100M RUN RATE @ OPHTHALMIC SURGERY Formulations include antibiotics, anti-inflammation, sedation, mydriatics, and $1+ billion drug market “4.6M ocular surgeries and other procedures!*.8.10.1217 Demographic growth in the ov
Slide 10: Equity & Royalty Interests
EQUITY & ROYALTY INTERESTS PHARMACEUTICALS ING pharmaceuticals L
Slide 11: Eton Pharmaceuticals
elon pharmaceuticals WHAT IS IT? + Focus on drug candidates requiring single small PIll trials, bio-equivalence, or literature-based 505(b)(2) NDA filings + Current portfolio contains eight product candidates with an addressable market of > $4.4 billion: + Two products filed with the FDA and expecte
Slide 12: Surface Pharmaceuticals
Gurface PHARMACEUTICALS INC WHAT IS IT? + Focused on >$1B ocular surface disease and related markets + Imprimis contributed 505(b)(2) drug candidates have up to five indications: + Dry eye disease (chronic, episodic and refractory), pain and inflammation post ocular surgery, and blepharitis + Patent
Slide 13: Melt Pharmaceuticals
MELT EXISIISINIEIEE © © © © WHAT IS IT? + Owns patented non-opioid sublingual sedation / analgesia drug candidates + “100 million U.S. procedures annually’ where Melt formulations could replace and/or augment IV sedation + Multi-billion dollar market opportunity (ophthalmology, dental, MRI claustrop
Slide 14: Summary of Launched 505(b)(2) Drug Development Companies
SUMMARY OF LAUNCHED 505(B)(2) DRUG DEVELOPMENT COMPANIES | COMPANY | [__DRUG CANDIDATE __| [MARKET OPPORTUNITY | | ROYALTY RATE | Synthetic Corticotropin (39 peptide AA) $11B+ Infantile Spasms, Rheumatoid Arthritis (Acthar Gel® 17 sales”) Sis Mycophenolic Acid + Klarity $1.5B+ 1% Chronic Dry Eye (Re
Slide 15: Summary
Slide 16: Key Takeaways
KEY TAKEAWAYS Our operating business is profitable; it’s an innovation engine; and on plan to reach a $100M revenue run rate in 2021 Growing balance sheet with equity positions in well funded and well managed 505(b)(2) pharmaceutical companies Significant income potential through royalty stakes in a
Slide 17: Company Profile
COMPANY PROFILE (as of December 13, 2018) TRADING SYMBOL: PRICE PER SHARE: STRONG CEO/CFO INCENTIVE THRU NASDAQ: IMMY PERFORMANCE STOCK UNITS TO $5.95 ACHIEVE $9 — $15 SHARE PRICE AVG. DAILY QTD TRADING VOLUME: SHARES OUTSTANDING: 406,000 SHARES 23 MILLION STOCK PRICE RANGE (52-WEEK): CORPORATE HEAD
Slide 18: Appendix and References
|_APPENDIX AND REFERENCES
Slide 19: Published Clinical Data
PUBLISHED CLINICAL DATA In a study of 483 eyes undergoing cataract surgery with concomitant trabecular microbypass stent insertion, there were no statistically significant differences in the safety profiles of a study group of 234 eyes receiving an intravitreal injection (pars plana) of 0.2mL of Dro
Slide 20: Reducing complexity of the pharmaceutical value chain
Imprimis We reduce the complexity of the pharmaceutical Value Chain, eliminating the need for: Insurance companies Pharmacy benefit managers (PBM) Wholesalers Distributors
Slide 21: References
@ REFERENCES Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May). Allen, A. (2007). Vasectomy Risks and Benefits. Retrieved November 08, 2016, from http://www.webmd.com/men/features/vasectomy- risks-benefits US Market Report Suite for Gastrointestinal Endoscopic Devices 2017
Slide 22: References
@ REFERENCES Irwin, K. (2012, December 10). Prostate cancer now detectable using imaging-guided biopsy, UCLA study shows. Retrieved January 08, 2017, from http://newsroom.ucla.edu/releases/prostate-cancer-now-detectable-241575 Centers for Disease Control and Prevention - United States, 2013. (2016,
Slide 23: Imprimis contact details
. e ° e e e*%e “Imprimis PALA RIMINS SINS 12264 EL CAMINO REAL, SUITE 350 “/ SAN DIEGO, CA 92130 (858) 704-4040 - IR@IMPRIMISPHARMA. COM WWW.|IMPRIMISRX.COM
Imprimis Pharmaceuticals — Investor Presentation (December 2018) on 6ix